Basic Information
Senseera is a liquid biopsy company headquartered in Jerusalem and a pioneer in chromatin epigenomics. Senseera's GEM (Genomic Expression Mapping) BIOMARKERS, established in 2020, is a novel biomarker discovery platform based on patented chromatin epigenomics (cfChIP-seq) liquid biopsy technology (Sadeh, Nature Biotechnology, 2021).
Senseera Health
Israel
15~50 people
January 01, 2020
info@senseerahealth.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios